February 26, 2026 (MLN): Ferozsons Laboratories Limited (PSX: FEROZ) has reported a healthy recovery in its financial performance for the half-year ended December 31, 2025, with post-tax profits climbing to PKR 353.6 million.

This marks a significant 40% increase from the Rs252.3 million recorded during the same period last year, driven by a combination of top-line expansion and savvy financial management.

The company’s net revenue grew by a steady 17.9%, crossing the Rs8.2 billion mark.

More impressively, Ferozsons managed to optimize its manufacturing costs, which only rose by 13.4%, leading to a much stronger Gross Profit margin of 41.6%.

While the company spent aggressively on marketing, with selling and distribution expenses rising by 30%, this investment clearly paid off in the form of higher sales volume.

A key catalyst for the bottom-line surge was a dramatic 45% reduction in finance costs, which fell from Rs275.8 million to Rs152 million. 

 The strong operational results translated into Earnings Per Share (EPS) of Rs8.13, up from Rs5.80 in the previous year.

Despite a higher tax bill of Rs233 million, the company has demonstrated robust resilience and proved that its core pharmaceutical business remains on a strong upward trajectory in a competitive landscape.

Copyright